Wełnicki, M. (2025). Why we choose fenofibrate? Fenofibrate in long-term therapy – larger packages, greater benefits for patients with atherogenic dyslipidemia. Medycyna Faktow (J EBM), 18(2(67), 290-292. https://doi.org/10.24292/01.MF.0225.18